Applications of N-Boc-Piperidine-4-Carboxylic Acid Methyl Ester in Industrial Manufacturing

N-Boc-Piperidine-4-Carboxylic Acid Methyl Ester serves as a critical intermediate for the synthesis of various high-value finished chemicals. As a manufacturer, we support specialized needs in pharma actives, peptide building blocks, crop protection, and diagnostic reagents, where strict compliance and precise process control are essential.

1. Active Pharmaceutical Ingredient (API) Intermediate Synthesis

This material is widely used as a protected amine intermediate in the multistep synthesis of selective serotonin reuptake inhibitor (SSRI) APIs as well as advanced anti-viral and oncology agents. Manufacturers utilize its Boc-protected piperidine scaffold to reduce side-reactions during peptide bond formation or heterocycle expansion. It allows for smooth deprotection under acidic conditions, ensuring minimal impurity profiles. Process engineers integrate this compound specifically in the amidation and alkylation phases, supporting stringent traceability for regulated markets targeting human medicinal products.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients
• USP/NF monographs (USP General Chapter <797>, <1078>)
• European Pharmacopoeia (Ph. Eur.) raw material guidelines
• 21 CFR Part 211 for Finished Pharmaceuticals

Typical usage ratio

• Stoichiometric 1.0–1.2 molar equivalents relative to the core amine in API synthesis, adjusted based on target yield and step economy

Downstream process integration

• Charged during intermediate elongation steps via solvent-based couplings
• Subjected to in-process HPLC purity control before deprotection or further transformation

Final product types

• SSRIs (e.g., Paroxetine intermediates)
• Integrase inhibitors
• Hepatitis C antivirals
• Cancer therapy precursors

2. Peptide Synthesis Building Block

Chemical peptide manufacturers rely on this compound in solid- and solution-phase peptide assembly, leveraging its N-Boc protection to safeguard piperidine nitrogen during automated chain elongation. The compound integrates seamlessly into Fmoc/Boc strategies, ensuring orthogonality and structural integrity during repeated deprotection and coupling cycles. Peptide houses emphasize high purity inputs, controlling racemization and byproduct formation to meet downstream biopharmaceutical batch release specifications.

Industry compliance standards

• European Pharmacopoeia 10.0, Chapter 07 “Peptides”
• ICH Q11 Development and Manufacture of Drug Substances
• US FDA CFR Title 21 Part 210/211, applicable to peptide therapeutics
• ISO 13485 for medical-grade peptide components

Typical usage ratio

• Between 0.8–1.0 molar equivalents per peptide elongation step; varies with chain length and resin substitution rate

Downstream process integration

• Introduced during N-terminal protection/capping cycles on automated peptide synthesizers
• Subjected to parallel solid-phase washes and stepwise coupling validation (UPLC/MS control)

Final product types

• GMP-grade therapeutic peptides
• Peptide API building blocks
• Diagnostic peptide reagents
• Research peptides for molecular probes

3. Agrochemical Active Intermediate Manufacturing

Chemical suppliers in the crop protection sector use the material’s piperidine core for the synthesis of advanced intermediates for insecticide and fungicide actives. The N-Boc group enables selective functionalization during ring substitution and subsequent derivatization, crucial for constructing piperidine-derived pesticide scaffolds under controlled reaction conditions. The typical workflow includes multi-step transformations for patent-protected molecule production, demanding robust impurity and residual solvent controls aligned with agrochemical regulatory audits.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• FAO/WHO Specifications for Plant Protection Products
• REACH (EC) No 1907/2006 for chemical substances
• China GB2763 Maximum Residue Limits for Pesticides Standards

Typical usage ratio

• 0.5–1.0 molar equivalent per core agro-intermediate formation; adjusted for downstream cost and process yield

Downstream process integration

• Employed in batchwise or continuous flow synthesis of active piperidine derivatives
• Subjected to inline GC/MS analysis to track residual N-Boc content pre-final step

Final product types

• Piperidine-based fungicides
• Selective herbicide intermediates
• Novel insecticide scaffolds
• Synergist adjuvant precursors

4. Diagnostic and Imaging Reagent Precursor

Producers of diagnostic and imaging kits utilize this ester in the preparation of functionalized ligands and radiolabel precursors. The controlled reactivity and protective capabilities enable chemical vendors to introduce piperidine units into chelating agents or tagged antibody linkers. Its purity specifications align with strict analytical criteria, mitigating side-products that may interfere with detection or imaging sensitivity. End-users rely on the reproducibility and trace-level contaminant profile maintained by industrial production standards.

Industry compliance standards

• ISO 13485:2016 for medical device reagents
• CLSI (Clinical & Laboratory Standards Institute) guidelines for diagnostic raw materials
• EU Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)
• 21 CFR Part 820 for Quality Systems Regulation in medical diagnostics

Typical usage ratio

• 0.2–0.7 molar ratio relative to chelating framework or linker system, depending on target ligand density

Downstream process integration

• Added during the conjugation phase of imaging agent synthesis
• Subjected to HPLC/MS batch release criteria for radiopurity and structural confirmation

Final product types

• PET and SPECT imaging precursors
• Fluorescent probe intermediates
• Antibody-drug conjugate linkers
• Blood marker assay components